TY - JOUR
T1 - Cells, scaffolds, and molecules for myocardial tissue engineering
AU - Leor, Jonathan
AU - Amsalem, Yoram
AU - Cohen, Smadar
PY - 2005/2
Y1 - 2005/2
N2 - Unlike heart valves or blood vessels, heart muscle has no replacement alternatives. The most challenging goal in the field of cardiovascular tissue engineering is the creation/ regeneration of an engineered heart muscle. Recent advances in methods of stem cell isolation, culture in bioreactors, and the synthesis of bioactive materials promise to create engineered cardiac tissue ex vivo. At the same time, new approaches are conceived that explore ways to induce tissue regeneration after injury. The purpose of our review is to describe the principles, status, and challenges of myocardial tissue engineering with emphasize on the concept of in situ cardiac tissue engineering and regeneration.
AB - Unlike heart valves or blood vessels, heart muscle has no replacement alternatives. The most challenging goal in the field of cardiovascular tissue engineering is the creation/ regeneration of an engineered heart muscle. Recent advances in methods of stem cell isolation, culture in bioreactors, and the synthesis of bioactive materials promise to create engineered cardiac tissue ex vivo. At the same time, new approaches are conceived that explore ways to induce tissue regeneration after injury. The purpose of our review is to describe the principles, status, and challenges of myocardial tissue engineering with emphasize on the concept of in situ cardiac tissue engineering and regeneration.
KW - Biomaterial
KW - Cell
KW - Heart
KW - Scaffold
KW - Tissue engineering
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=12844288101&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2004.10.003
DO - 10.1016/j.pharmthera.2004.10.003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:12844288101
VL - 105
SP - 151
EP - 163
JO - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
JF - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
SN - 0163-7258
IS - 2
ER -